323 related articles for article (PubMed ID: 6446379)
1. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
[No Abstract] [Full Text] [Related]
2. Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization.
Mokyr MB; Hengst JC; Przepiorka D; Dray S
Cancer Res; 1979 Oct; 39(10):3928-34. PubMed ID: 157800
[No Abstract] [Full Text] [Related]
3. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
4. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
Hengst JC; Mokyr MB; Dray S
Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
6. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
7. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
8. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
9. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
Osborne DP; Katz DH
J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
[TBL] [Abstract][Full Text] [Related]
10. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
11. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
Platica M; Bojko C; Steiner G; Hollander VP
Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation of antitumor response by chemotherapy.
Ben-Efraim S
Contrib Gynecol Obstet; 1985; 14():199-205. PubMed ID: 2933224
[No Abstract] [Full Text] [Related]
13. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
Gorelik L; Rubin M; Prokhorova A; Mokyr MB
J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
[TBL] [Abstract][Full Text] [Related]
14. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
[TBL] [Abstract][Full Text] [Related]
15. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
Braun DP; Mokyr MB; Dray S
Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activation.
Mokyr MB; Braun DP; Dray S
Cancer Res; 1979 Mar; 39(3):785-92. PubMed ID: 427766
[No Abstract] [Full Text] [Related]
17. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
[TBL] [Abstract][Full Text] [Related]
18. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
Haubeck HD; Kölsch E
Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
[TBL] [Abstract][Full Text] [Related]
19. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
Mokyr MB; Hengst JC; Dray S
Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
[TBL] [Abstract][Full Text] [Related]
20. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]